Other adverse outcomes · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Mortality Mortality at latest · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids showed no clear difference in mortality at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
BPD (36 weeks' PMA) · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids probably leads to lower BPD (36 weeks' PMA) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to lower mortality or BPD at 36 weeks' PMA compared with placebo or no treatment (high certainty).
1 finding from 1 review
Gastrointestinal perforation during primary hospitalisation · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to higher gastrointestinal perforation during primary hospitalisation compared with placebo or no treatment (high certainty).
1 finding from 1 review
Cerebral palsy · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to higher cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
Death or cerebral palsy · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids showed no clear difference in mortality or cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
Mean number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Depot corticosteroids (systemic; 40 mg methylprednisolone IM every 3… showed no clear difference in mean number of oral ulcers compared with placebo (saline IM injection); GRADE not reported.
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Episode duration associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Pain associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review